miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 667-673

  Zhang, Jian Wen ^a   Li, Yang ^a   Zeng, Xian Cheng ^b   Zhang, Tong ^a   Fu, Bin Sheng ^a   Yi, Hui Min ^a   Zhang, Qi ^a   Jiang, Nan ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alpha Fetoproteins; Carcinoma, hepatocellular; MicroRNAs

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA FETOPROTEIN ANTIBODY; COMPLEMENTARY DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MICRORNA; MICRORNA 630; UNCLASSIFIED DRUG; MIRN630 MICRORNA, HUMAN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; BLOOD; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING;

EID: 84925114209     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892515     Document Type: Article

References (38)

1. Yuen MF, Hou JL, Chutaputti A: Asia Pacific Working Party on Prevention of Hepatocellular C. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 2009; 24: 346-53.
2. Jemal A, Bray F, Center MM et al: Global cancer statistics. Cancer J Clin, 2011; 61: 69-90.
3. Elzouki AN, Elkhider H, Yacout K et al: Metastatic hepatocellular carcinoma to parotid glands. Am J Case Rep, 2014; 15: 343-47.
4. Hao K, Luk JM, Lee NP et al: Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer, 2009; 9: 389.
5. Li C, Zhao H, Zhao J et al: Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China. Onco Targets Ther, 2014; 7: 957-64.
6. Zhou YM, Zhang XF, Yu F et al: Efficacy of surgical resection for pulmonary metastases from hepatocellular carcinoma. Med Sci Monit, 2015; 21: 1544-49.
7. Wang BF, Lin S, Bai MH et al: Effects of SSd combined with radiation on inhibiting SMMC-7721 hepatoma cell growth. Med Sci Monit, 2015; 21: 1340-44.
8. Lu J, Xu L, Zou Y et al: IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Med Sci Monit, 2015; 21: 247-54.
9. Taura N, Ichikawa T, Miyaaki H et al: Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit, 2013; 19: 742-50.
10. Rutnam ZJ, Yang BB: The involvement of microRNAs in malignant transformation. Histol Histopathol, 2012; 27: 1263-70.
11. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M: microRNAs in cancer management. Lancet Oncol, 2012; 13: e249-58.
12. Di Leva G, Garofalo M, Croce CM: MicroRNAs in cancer. Annu Rev Pathol, 2014; 9: 287-314.
13. Law PT, Qin H, Ching AK et al: Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol, 2013; 58: 1165-73.
14. ElHefnawi M, Soliman B, Abu-Shahba N, Amer M: An integrative metaanalysis of microRNAs in hepatocellular carcinoma. Genomics Proteomics Bioinformatics, 2013; 11: 354-67.
15. Wei R, Huang GL, Zhang MY et al: Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res, 2013; 19: 4780-91.
16. Morishita A, Masaki T: miRNA in hepatocellular carcinoma. Hepatol Res, 2014 [Epub ahead of print].
17. Imbeaud S, Ladeiro Y, Zucman-Rossi J: Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis, 2010; 30: 75-86.
18. Guo J, Friedman SL: The expression patterns and clinical significance of microRNAs in liver diseases and hepatocellular carcinoma. Curr Pharm Des, 2013; 19: 1262-72.
19. Schrauder MG, Strick R, Schulz-Wendtland R et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 2012; 7: e29770.
20. Fu SW, Chen L, Man YG: miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer, 2011; 2: 116-22.
21. Wang L, Yao M, Dong Z et al: Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol, 2014; 35: 9-20.
22. Borel F, Konstantinova P, Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol, 2012; 56: 1371-83.
23. Toffanin S, Villanueva A, Llovet JM: miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology, 2010; 138: 1202-4.
24. Galluzzi L, Morselli E, Vitale I et al: miR-181a and miR-630 regulate cisplatin- induced cancer cell death. Cancer Res, 2010; 70: 1793-803.
25. Huang Y, Chuang A, Hao H et al: Phospho-DeltaNp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ, 2011; 18: 1220-30.
26. Huang Y, Guerrero-Preston R, Ratovitski EA: Phospho-DeltaNp63alphadependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle, 2012; 11: 1247-59.
27. Farhana L, Dawson MI, Murshed F et al: Upregulation of miR-150* and miR- 630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One, 2013; 8: e61015.
28. Kuo TC, Tan CT, Chang YW et al: Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest, 2013; 123: 1082-95.
29. Corcoran C, Rani S, Breslin S et al: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer, 2014; 13: 71.
30. Zhao JJ, Chen PJ, Duan RQ et al: Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol, 2014; 7: 3318-23.
31. Chu D, Zheng J, Li J et al: MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol, 2014; 35(10): 9787-89.
32. Chu D, Zhao Z, Li Y et al: Increased microRNA-630 expression in gastric cancer is associated with poor overall survival. PLoS One, 2014; 9: e90526.
33. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004; 116: 281-97.
34. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I nonsmall cell lung cancer after surgical resection. Cancer Res, 2010; 70: 36-45.
35. Huang J, Zeng Y: Current clinical uses of the biomarkers for hepatocellular carcinoma. Drug Discov Ther, 2014; 8: 98-99.
36. Debruyne EN, Delanghe JR: Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta, 2008; 395: 19-26.
37. Toro A, Ardiri A, Mannino M et al: Effect of pre- and post-treatment alphafetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC Surg, 2014; 14: 40.
38. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer, 1989; 64: 1700-7.